DE102010004431A1 - Indikationserweiterung von Acetazolamid zur Behandlung der Migräne - Google Patents

Indikationserweiterung von Acetazolamid zur Behandlung der Migräne Download PDF

Info

Publication number
DE102010004431A1
DE102010004431A1 DE102010004431A DE102010004431A DE102010004431A1 DE 102010004431 A1 DE102010004431 A1 DE 102010004431A1 DE 102010004431 A DE102010004431 A DE 102010004431A DE 102010004431 A DE102010004431 A DE 102010004431A DE 102010004431 A1 DE102010004431 A1 DE 102010004431A1
Authority
DE
Germany
Prior art keywords
migraine
acetazolamide
brain
pathogenesis
dura
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102010004431A
Other languages
English (en)
Inventor
Volker Waehnert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wahnert Volker 76889
Original Assignee
Wahnert Volker 76889
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wahnert Volker 76889 filed Critical Wahnert Volker 76889
Priority to DE102010004431A priority Critical patent/DE102010004431A1/de
Publication of DE102010004431A1 publication Critical patent/DE102010004431A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ich erhebe den Anspruch auf Grund meiner Erkenntnis über die Pathogenese der Migräne die einzige korrekte kausale Therapie in der Beseitigung des perivaskulären Ödems der Duragefäße des Gehirns mit Hilfe von Acetazolamid und somit der Behandlung des Migräneschmerz erkannt zu haben.

Description

  • Kausale Therapie der Migräne mit Acetazolamid in Erweiterung der bestehenden Indikation von Acetazolamid.
  • Die Basis der erweiterten Anwendung von Acetazolamid ist die von mir richtig erforschte Pathogenese der Migräne wie folgt:
    • 1. auslösende Faktoren bewirken eine übermäßige Serotoninausschüttung in begrenzten Hirnarealen.
    • 2. Dieses Serotonin erhöht in den Wänden der DURA MATER-Gefäße die Permeabilität für Blutflüssigkeit.
    • 3. jetzt dringt vermehrt Blutflüssigkeit in das die Duramater-Gefäße umgebende Hirngewebe
    • 4. dieses ödematöse Hirngewebe drückt auf die Duramater-Gefäße
    • 5. nur Duramater-Gefäße besitzen im Gehirn Schmerzrezeptoren.,
    • 6. die Signale aus diesen Schmerzrezeptoren lösen den Migräneschmerz aus.
  • Folgerichtig setze ich zur Beseitigung des Hirnödems = Migräne, das adäquate Medikament Acetazolamid (Diamox) ein.

Claims (1)

  1. Ich erhebe den Anspruch auf Grund meiner Erkenntnis über die Pathogenese der Migräne die einzige korrekte kausale Therapie in der Beseitigung des perivaskulären Ödems der Duragefäße des Gehirns mit Hilfe von Acetazolamid und somit der Behandlung des Migräneschmerz erkannt zu haben.
DE102010004431A 2010-01-13 2010-01-13 Indikationserweiterung von Acetazolamid zur Behandlung der Migräne Withdrawn DE102010004431A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE102010004431A DE102010004431A1 (de) 2010-01-13 2010-01-13 Indikationserweiterung von Acetazolamid zur Behandlung der Migräne

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010004431A DE102010004431A1 (de) 2010-01-13 2010-01-13 Indikationserweiterung von Acetazolamid zur Behandlung der Migräne

Publications (1)

Publication Number Publication Date
DE102010004431A1 true DE102010004431A1 (de) 2011-07-14

Family

ID=44313062

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102010004431A Withdrawn DE102010004431A1 (de) 2010-01-13 2010-01-13 Indikationserweiterung von Acetazolamid zur Behandlung der Migräne

Country Status (1)

Country Link
DE (1) DE102010004431A1 (de)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Andrew M. Luks, Erik R. Swenson. Medication and Dosage Considerations in the Prophylaxis and Treatment of High-Altitude Illness. In: Chest, 133, 2008 744-755 *
F. Devetag Chalaupka. Therapeutic effectiveness of acetazolamide in hindbrain hernia headache. In: Neurological Sciences, 21(2), 2000, 117-119 *
Hans-Peter Schlake [et al.]. The influence of acetazolmide on cerebral low-flow regions in migraine: An interictal technetium-99m HMPAO SPECT study. In: Cephalalgia, 12 (5), 1992, 284-288 *
Jeffrey H. Gertsch [et al.]: Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT) *
Lalania K. Schexnayder, Kevin Chapman. Presentation, investigation and management of idiopathic intracranial hypertension in children. In: Current Pediatrics 16, 2006, 336-341 *
Robert Berkow, Mark H. Beers, Andrew J. Fletcher: MSD Manual-Handbuch Gesundheit, München: Mosaik, 1999, 1339-1341. ISBN3-576-11171-9 *
Rote Liste 2007. Frankfurt/Main, Verlag Rote Liste Service GmbH, Nr. 67 100 *
Tamara Shiner, Timothy Harrower, Gordon Plant: Acetazolamide and Symptoms Due to Low Intracranial Pressure in Idiopathic Intracranial Hypertension. In: Neuro-Ophtalmology, 32(5), 2008, 253-255 *

Similar Documents

Publication Publication Date Title
ATE485061T1 (de) Filterungssystem zur herstellung von flüssigkeiten für medizinische anwendungen
BR112015023267A8 (pt) composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido
BR112018007026A2 (pt) composto, método de modulação da atividade de gaba-at, método para a modulação dos níveis de dopamina, método para o tratamento da dependência de substâncias, método de modulação da atividade de ornitina aminotransferase, método de redução da atividade de uma ornitina aminotransferase expressa por um carcinoma hepatocelular humano e método para o tratamento de distúrbios psicológicos e neurológicos
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
IN2012DN04918A (de)
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
EP2431541A3 (de) Verfahren zur Applikation eines Wirkstoffs in Duschwasser
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
Rastmanesh et al. Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
DE102010004431A1 (de) Indikationserweiterung von Acetazolamid zur Behandlung der Migräne
AT508033A3 (de) Massierbehälter
UA105536C2 (uk) Пристрій для очищення води
MX2016012324A (es) Tratamiento de trastornos epilepticos en animanles felinos.
MX2018006960A (es) Composiciones que comprenden epicatequina 3'-o-glucuronido y metodos para preparar y usar esas composiciones.
AT509444B8 (de) Medizinisches gerät, konzentrat und methode zur wasseraufbereitung
WO2015070050A8 (en) Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
CN203295248U (zh) 新型采油注水消毒装置
RU2012150613A (ru) Способ уничтожения борщевика
CN202920588U (zh) 中医刮痧治疗器
EA201201408A1 (ru) Водоочистительное устройство
UA94915U (uk) Спосіб діагностики вестибулярної дисфункції у хворих зі струсом головного мозку у гострому періоді черепно-мозкової травми
ATE553740T1 (de) Vorrichtung zum behandeln von hautkrankheiten mittels kangalfischen und verfahren zum betreiben der vorrichtung
CN109125477A (zh) 一种治疗头皮屑的药物

Legal Events

Date Code Title Description
R016 Response to examination communication
R016 Response to examination communication
R002 Refusal decision in examination/registration proceedings
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee